GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 232 filers reported holding GENMAB A/S in Q4 2022. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,889,417 | -9.0% | 450,508 | -2.0% | 0.01% | -7.7% |
| Q2 2023 | $17,466,963 | -25.1% | 459,536 | -25.6% | 0.01% | -27.8% |
| Q1 2023 | $23,320,123 | -9.8% | 617,588 | +1.2% | 0.02% | -14.3% |
| Q4 2022 | $25,867,862 | +35.6% | 610,379 | +2.8% | 0.02% | +23.5% |
| Q3 2022 | $19,079,000 | -2.6% | 593,810 | -1.5% | 0.02% | +6.2% |
| Q2 2022 | $19,596,000 | +28.7% | 603,150 | +43.3% | 0.02% | +60.0% |
| Q1 2022 | $15,226,000 | +866.1% | 420,839 | +956.7% | 0.01% | +900.0% |
| Q4 2021 | $1,576,000 | -6.1% | 39,826 | +3.7% | 0.00% | 0.0% |
| Q3 2021 | $1,678,000 | +39.8% | 38,402 | +30.6% | 0.00% | 0.0% |
| Q2 2021 | $1,200,000 | +27.1% | 29,396 | +2.2% | 0.00% | 0.0% |
| Q1 2021 | $944,000 | +15.7% | 28,756 | +43.3% | 0.00% | 0.0% |
| Q4 2020 | $816,000 | +74.4% | 20,073 | +57.1% | 0.00% | – |
| Q3 2020 | $468,000 | +10.9% | 12,778 | +2.6% | 0.00% | – |
| Q2 2020 | $422,000 | – | 12,454 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |